Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...

Vivani Medical (VANI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...

About Cortigent, Inc. Cortigent, Inc., formerly Second Sight Medical Products and a wholly owned subsidiary of Vivani, is developing brain implant devices to help people recover critical body ...

Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter valued at $66,000. Wealthedge Investment Advisors LLC acquired a new stake in Vivani Medical in the 4th quarter ...

HC Wainwright reduced their FY2024 earnings estimates for shares of Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company ...